Representative images of TIMP2 expression from patients without and with primary endpoints.

<p>(A). Grade 2 (B). Grade 0 (original magnification 400×).</p

Semiquantitative scoring system for TIMP2 immunostaining.

<p>The samples were ranked into 3 grades based on the percentage of positive cells (see arrows): grade 0, negative (A); grade 1, positive staining in small number of cells (B); grade 2, positive staining in large number of cells (C) (original magnification 400×). TIMP2, tissue inhibitor of metalloproteinase.</p

Comparison of Baseline Characteristics and Medication between Patients with and without Primary Endpoint Events.

<p>LAD, left atrial diameter; LVESD, left ventricular end-systolic dimension; LVEDD, left ventricularend-diastolic dimension; RAS, renin-angiotensin system; ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blocker.</p

Kaplan-Meier estimates of (A) primary endpoints (B) cardiovascular death (C) admission for heart failure between different TIMP2 expression populations.

<p>(p = 0.004, 0.042 and 0.021, respectively). TIMP2, tissue inhibitor of metalloproteinase.</p

Multivariate Cox regression analysis of independent predictors of primary endpoints.

<p>TIMP2, tissue inhibitor of metalloproteinase; LVESD, left ventricular end-systolic dimension.</p

Correlation between TIMP2 and primary endpoints.

<p>Mean ± SD; TIMP2, tissue inhibitor of metalloproteinase.</p

Receiver operating characteristic curves for age and LVESD in the prediction of primary endpoints.

<p>LVESD, left ventricular end-systolic diameter.</p